You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
萬泰生物(603392.SH):公司九價HPV疫苗上市許可申請獲得批准
格隆匯 06-04 15:44

格隆匯6月4日丨萬泰生物(603392.SH)公佈,公司全資子公司廈門萬泰滄海生物技術有限公司申報的九價人乳頭瘤病毒疫苗(大腸埃希菌)(商品名稱:馨可寧9)獲批上市。

公司本次獲批的九價HPV疫苗覆蓋HPV16/18/31/33/45/52/58七種高危型和HPV6/11兩種低危型,可預防上述型別人乳頭瘤病毒感染引起的相關疾病。

此前全球範圍內僅有一款九價HPV疫苗上市,為默沙東的佳達修®9。佳達修®9於2018年在中國獲批,佳達修®9適用9-45歲女性,其中9-14歲可採用二劑次接種程序(0,6~12月),15-45歲採用三劑次接種程序(0,6月,12月)。公司本次獲批的九價HPV疫苗適用於9-45歲女性,其中9-17歲可採用二劑次接種程序(0、6月),18-45歲採用三劑次接種程序(0,6月,12月)。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account